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Background: This is the first cross-sectional study that aims to examine associations between 
beliefs about medication and non-adherence in patients with rheumatoid arthritis (RA) using 
disease-modifying antirheumatic drugs, taking potential psychological confounders into 
account.
Methods: Eligible patients (diagnosed with RA for 1 year or 18 years, using greater than 
or equal to one disease-modifying antirheumatic drug) were included by their rheumatologist 
during regular outpatient visits between September 2009 and September 2010. Included patients 
received questionnaires. The Beliefs about Medicines Questionnaire was used to measure the 
perceived need to take medication (necessity beliefs), the concerns about taking medication 
(concern beliefs), general medication beliefs, and attitudes toward taking medication. Medica-
tion non-adherence (no/yes) was measured using the Compliance Questionnaire Rheumatology 
(CQR). Associations between beliefs and non-adherence, and the influence of demographi-
cal, clinical, and psychological factors (symptoms of anxiety/depression, illness cognitions, 
self-efficacy) were assessed using logistic regression.
Results: A total of 580 of the 820 eligible patients willing to participate were included in the 
analyses (68% female, mean age 63 years, 30% non-adherent to their medication). Weaker 
necessity beliefs (OR [odds ratio]: 0.8, 95% CI [confidence interval]: 0.8–0.9) and an unfavor-
able balance between necessity and concern beliefs (OR: 0.9, 95% CI: 0.9–1.0) were associated 
with CQR non-adherence. Also, having an indifferent attitude toward medication (no/yes) 
was associated with CQR non-adherence (OR: 5.3, 95% CI: 1.1–25.8), but the prevalence of 
patients with an indifferent attitude toward medication was low. The associations were barely 
confounded by demographical, clinical, and psychological factors.
Conclusion: Increasing necessity beliefs about medication in clinical practice might be worth-
while in improving medication adherence in RA patients.
Keywords: medication non-adherence, medication beliefs, psychological confounders, cross-
sectional studies, rheumatoid arthritis
Introduction
Disease-modifying antirheumatic drugs (DMARDs) reduce disease activity and 
radiological progression, and improve long-term functional outcome in patients with 
rheumatoid arthritis (RA).1 However, adherence to DMARDs, ie, the extent to which a 
patient’s medication intake behavior corresponds with agreed recommendations from 
their health care provider,2 is not optimal and ranges from 22% (underuse) to 107% 
(overuse).3–7 DMARD non-adherence results in more disease activity/radiological 
damage, loss of function, and a lower quality of life.8–10 Moreover, the annual costs of 
non-adherence for all conditions in the US have been estimated to be $100 billion.11 
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In view of the negative implications of medication non-
adherence, effective interventions to improve medication 
adherence are warranted.
Recently, types of non-adherence have been conceptual-
ized as “unintentional” (eg, forgetting medicines)2 and “inten-
tional.” Intentional non-adherence is driven by a decision not 
to take medicines as prescribed. According to the Necessity-
Concerns Framework of Horne and Weinman,12 it is assumed 
that intentional adherence decisions are influenced by a cost–
benefit assessment. Herein, personal beliefs (assumptions 
and convictions that are believed to be true by an individual) 
about the necessity of taking the medication for maintaining 
or improving health are balanced against concerns about the 
potential adverse effects (such as nausea and abnormal liver 
and blood tests,13 and also adverse effects like actual medica-
tion costs for patients)14 of taking the medication.
Many studies underline the importance of addressing 
these necessity beliefs and concern beliefs about medication 
to improve adherence. In RA, four studies assessed associa-
tions between medication non-adherence and necessity and 
concern beliefs about medication (measured with the Beliefs 
about Medicines Questionnaire [BMQ]).15–18 In three of the 
four studies, stronger necessity beliefs were associated with 
better medication adherence,16–18 whereas in one other study, 
stronger concern beliefs were associated with decreased 
medication adherence.15 Although those studies provide some 
guidance in targeting the most relevant medication beliefs in 
clinical practice, they have some limitations.
First, only one of the four studies assessing associations 
between medication beliefs and non-adherence in RA patients 
used a valid adherence measure (the dichotomized Compli-
ance Questionnaire Rheumatology [CQR] score,17 which was 
validated against the Medication Event Monitoring System 
[MEMS]; see Supplementary materials).19 Using unvali-
dated adherence measures might undermine the validity of 
associations found.
Second, medication beliefs other than necessity and 
concern beliefs measured with the BMQ are suggested to 
be associated with non-adherence16,20–22 but are not often 
included in the existing research. These constructs comprise 
four attitudinal patient profiles toward taking medication (ie, 
“skeptical”, “indifferent”, “ambivalent”, and “accepting”), 
and general beliefs about the potential of medication to harm 
and about overuse of medication by clinicians. In RA, only 
one study assessed associations between the general medica-
tion beliefs and adherence. This study demonstrated that the 
belief that physicians do not overuse medication was related 
to better adherence.16 More studies are needed, however, to 
know the extent to which these constructs are associated with 
medication non-adherence in RA patients.
Third, no single study (in- and outside the field of 
RA) examining associations between medication beliefs 
and non-adherence took psychological factors such as 
anxiety/depression, self-efficacy, and illness cognitions 
simultaneously into account in the data-analysis, while 
they appear to play a central role in explaining medication 
non-adherence.23,24 These factors might also be associated 
with beliefs about medication, moreover, and might thus be 
potential confounders of associations between beliefs about 
medication and non-adherence. It is conceivable that patients 
with stronger accepting cognitions about their illness also 
have more positive views about their medication, and thus, 
have better medication adherence than patients who do not 
accept their illness, for example.
The aim of this cross-sectional study is to examine asso-
ciations between the total range of beliefs about medication 
(as measured with the BMQ) and medication non-adherence 
in RA patients using DMARDs, using the dichotomized 
CQR adherence measure, and taking potential psychologi-
cal, demographical, and clinical confounders into account. 
The results of our study could provide starting points for the 
development of interventions to improve adherence.
Patients and methods
This study is approved by the local medical ethical board 
(CMO 2009/090) and is reported according to the Strengthen-
ing the Reporting of Observational Studies in Epidemiology 
guidelines.25
Design, patients, and procedure
This cross-sectional study was conducted at the Sint Maarten-
skliniek (a clinic specializing in rheumatology, rehabilita-
tion, and orthopedic surgery) in Nijmegen, the Netherlands. 
Consecutive RA patients were screened for eligibility by 
their rheumatologist during regular outpatient visits between 
September 2009 and September 2010. Inclusion criteria were 
having RA for at least 1 year (because medication beliefs are 
still to be formed in patients newly diagnosed with RA)26 
according to the 2010 American College of Rheumatology 
criteria,27 being 18 years old, and using 1 prescribed 
DMARD. Having severe mental or physical constraints and 
being illiterate in the Dutch language were exclusion criteria. 
Eligible patients willing to participate received study infor-
mation and a set of questionnaires at their home address. 
Reminders were sent after 2 weeks. All included patients 
had signed informed consent.
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Measures
Unless indicated otherwise, items were measured by self-
report questionnaires.
Beliefs about medication
Beliefs about medication were measured using two parts 
of the validated BMQ:28 the BMQ “specific” and the BMQ 
“general.”
The BMQ “specific” has two subscales of five items each, 
measuring patients’ beliefs about the necessity of prescribed 
medication (eg, “Without my medicines I would be very ill”) 
and their concerns about potential adverse consequences of 
taking the medication. Within the subscales, items are scored 
from 5 (strongly agree) to 1 (strongly disagree) and are summed 
to obtain a total score ranging from 5 to 25. Higher scores indi-
cate stronger beliefs. By subtracting the concern score from 
the necessity score, a necessity–concerns differential score 
can be calculated (ranging from -20 to +20, where positive 
scores mean that patients perceive that benefits of medication 
outweigh costs, and vice versa). Necessity and concern scores 
were dichotomized at the scale midpoint to create four attitu-
dinal profiles: “skeptical” (low necessity, high concerns [score 
15 or 15, respectively]), “indifferent” (low necessity, low 
concerns), “ambivalent” (high necessity, high concerns), and 
“accepting” (high necessity, low concerns).20,22
The BMQ “general” assesses general beliefs about phar-
maceuticals as a class of treatment,20 and has two subscales 
of four items each. The “overuse” subscale includes beliefs 
about the way in which medicines are endorsed by doctors 
(eg, “Doctors place too much trust on medicines”). The 
“harm” subscale includes beliefs about the potential of medi-
cation to harm (eg, “Medicines do more harm than good”). 
The scoring method is identical to the BMQ “specific”: total 
subscale scores range from 4 to 20.
Medication non-adherence
Medication non-adherence was primarily assessed with the 
CQR. The CQR has been validated using MEMS in RA 
patients,19 and is able to detect whether a patient takes 80% 
of prescribed medication (binary score: non-adherent versus 
adherent patients) with a sensitivity of 62% and a specific-
ity of 95%. Details about calculation of the CQR-score are 
provided in the Supplementary materials section.
The five-item Medication Adherence Report Scale 
(MARS)29 was used as an alternative measure for non-adherence 
in a sensitivity analysis. MARS includes statements about 
stopping, forgetting, or altering medication doses. Items are 
summed to obtain a total score ranging from 5 to 25, where 
higher scores meant better adherence. Because the MARS 
score was severely skewed in this study, we dichotomized 
the score at 95% of its scale (non-adherent when total 
score 23).17,30
Potential confounders
Sociodemographic factors measured were age, sex, living 
with others (yes/no), educational level (high/not high, where 
“high” means having at least a bachelor or master degree), 
and employment/studying (yes/no).
Clinical factors measured were disease duration, disease 
activity (Rheumatoid Arthritis Disease Activity Index),31 
pain (Visual Analog Scale),32,33 and physical abilities (Health 
Assessment Questionnaire);32 see Table S1 for details. Elec-
tronic hospital/pharmacy data34 were used to assess the types 
of DMARDs taken at the time of filling in the questionnaires 
and to assess the presence of anti-CCP (cyclic citrullinated 
peptide antibody) and rheumatoid factor values in the par-
ticipants (for descriptive purposes only).
Three psychological factors were measured. The Illness 
Cognition Questionnaire35 encompasses three generic illness 
cognitions, namely “helplessness” as a way of emphasizing 
the aversive meaning of a disease, “acceptance” as a way to 
diminish this aversive meaning, and “perceived benefits” as 
a way of adding a positive meaning to a disease. Self-efficacy 
related to physical function, to coping with pain, and to cop-
ing with other symptoms associated with arthritis (such as 
depression and fatigue) was measured with the Arthritis Self-
Efficacy Scale.36,37 Last, feelings of anxiety/depression were 
measured by the Hospital Anxiety and Depression Scale.38 
For details about the questionnaires, see Table S1.
All questionnaires used are validated tools and demon-
strated to have a sufficient internal consistency in this RA 
sample. Cronbach’s alpha varied from 0.68 to 0.97.
sample size and data analyses
As we aimed to adjust for approximately 25 variables in our 
data analyses, we aimed to include at least 500 RA patients 
in this cross-sectional study.39
Differences between study participants and patients who 
refused to participate were tested by means of chi-square 
tests, two sample t-tests, or non-parametric tests in case of 
skewed distributions. Then, correlation coefficients between 
all pairs of variables were studied to detect multicollinearity: 
non-psychological factors were removed from further analy-
ses when r80 (oral conversation with Drs P Spreeuwenberg, 
statistician, NIVEL, September 2013). The psychological 
factors were all included in further analyses to study their 
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influence on associations between beliefs about medication 
and non-adherence.
Subsequently, associations between all scales of beliefs 
about medication and non-adherence were analyzed by 
logistic regression models in three steps, with robust standard 
errors40 and a two-sided α set at 0.05. Univariate, unadjusted 
models were fit in Step 1. In Step 2, demographic and clinical 
measures were forced into the models attained in Step 1, and 
in the last step, the psychological factors were forced into 
the models attained in Step 2. In a sensitivity analysis, we 
repeated all steps with the MARS as a non-adherence mea-
sure. Note that the four attitudinal profiles (Measures sec-
tion) were handled as dichotomous variables in the analyses 
(eg, patients with a skeptical attitude versus the rest of the 
patients, whereby “the rest of the patients” were the refer-
ence group).
Analyses were performed in STATA10, were based on 
complete cases, and were verified by a statistician.
Results
Participants
A total of 580 (71%) of the 820 eligible patients willing to 
participate were included in the analyses (Figure 1). The 
580 patients who returned the questionnaires did not differ 
on age and sex from the 240 patients who did not return the 
questionnaires.
Most participants were female and lived together with 
other people. Less than 20% of the participants were highly 
educated. Also, the majority of participants used one DMARD 
and had a median disease duration of 14 years (Table 1).
non-adherence and psychological factors
In all, 171 of 575 of participants filling in the CQR were 
non-adherent to their medication (29.7%). This was 33.6% 
(of 562 participants) according to the MARS. The correlation 
between the two adherence measures was low (Spearman’s 
rho =0.28, P0.01).
Participants had stronger necessity beliefs than concern 
beliefs about medication, and the majority of participants had 
an accepting or ambivalent attitude toward their DMARD 
medication (Table 2).
Associations between beliefs about 
medication and non-adherence
Unadjusted and adjusted associations between the BMQ 
constructs and CQR non-adherence are displayed in Table 3. 
Planned eligibility screening by
rheumatologist
n=1,075
Not screened (n=167)
Objection of patients n=115
Not enough time for screening during outpatient visit n=52
Non-response due to (n=240)
n=14
n=11
n=4
n=211
Personal conditions (eg, considering oneself too old,
too weak, too busy, family affairs)
Questionnaire content (eg, too many or too personal
questions)
Not using medication at that time
Questionnaire not returned, reasons unknown
Not eligible (n=88)
No rheumatoid arthritis n=22
n=13
n=16
n=12
n=11
n=8
n=6
No use of DMARDs
Not able to participate, mentally
Not able to participate, physically
Not able to participate, communicatively
Objection of rheumatologist, unknown reasons
Objection of rheumatologist, multiple of above reasons
Screened for eligibility by
rheumatologist/assistant
n=908
Eligible, questionnaires sent
n=820
Questionnaires returned and analyzed
n=580
Figure 1 Participant flow chart.
Abbreviation: DMArDs, disease-modifying antirheumatic drugs.
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The significant associations between continuously measured 
BMQ constructs and non-adherence of Step 3 (Table 3) are 
also visually presented in Figure 2.
The Health Assessment Questionnaire-scale was removed 
from the analyses due to multicollinearity with the Arthritis 
Self-Efficacy Scale physical functioning scale.
After adjustment of all potential confounders, (weaker) 
necessity beliefs, a more unfavorable balance between 
necessity and concern beliefs, and having an indifferent 
attitude toward medication were associated with CQR non-
adherence. The post hoc analysis revealed that patients with 
an indifferent attitude toward medication were less adherent 
to medication compared to patients with an ambivalent or 
accepting attitude (chi-square tests, P=0.001). Overall, the 
general medication beliefs (the harm and overuse scales) 
were not associated with non-adherence.
Demographical and clinical factors barely influenced 
associations between beliefs about medication and CQR 
non-adherence (Step 2, Table 3), as did the psychological 
factors (Step 3, Table 3). The significant association between 
having an indifferent attitude toward medication and non-
adherence, however, was confounded by illness cognitions 
(perceived benefits of the disease). For details about the contri-
bution of single, psychological factors to associations between 
beliefs about medication and non-adherence, see Table S2.
sensitivity analysis
We repeated all analyses with the MARS (data not shown). 
Now, only (weaker) necessity beliefs about medication were 
associated with MARS non-adherence after adjustment for 
all confounders (odds ratio [OR]: 0.9, 95% CI: 0.8–1.0). 
Findings were robust regarding the role of demographical, 
clinical, and psychological confounders.
Discussion
This is the first cross-sectional study that assessed associa-
tions between the total range of beliefs about medication as 
measured with the BMQ and medication non-adherence in 
a large sample of patients with RA, using a valid adherence 
Table 1 sample characteristics
Variables Number of  
patients  
providing data
Descriptives
sociodemographic factors
Age (years) 580 62.8 (12.6)
Female 580 396 (68.3%)
living with others 571 458 (80.2%)
high education# 571 106 (18.6%)
currently employed or studying 552 216 (39.1%)
clinical factors
Disease duration (years) 556 14 (8–22)
number of DMArDs used
One DMArD 476 307 (64.5%)
Two DMArDs 476 149 (31.3%)
Three DMArDs 476 20 (4.2%)
route of DMArD administration
Oral‡ 476 272 (57.1%)
Parenteral§ 476 296 (62.2%)
rheumatoid factor (positive)װ 332 260 (78.3%)
Anti-ccP (positive)װ 284 199 (70.1%)
rADAi disease activity  
(0–10)¶
493 2.7 (1.9)
VAs pain score  
(0–100 mm)¶
550 30.8 (22.4)
hAQ-Di (0–3)¶ 563 1.1 (0.8)
Notes: Data are means (standard deviation), medians (interquartile range), or 
numbers (%). #high education means having at least a bachelor or master degree. 
‡Azathioprine, hydroxychloroquine, leflunomide, methotrexate, predinosone/
predinsolone, or sulfasalazine. §Adalimumab, aurothiomalate, methylprednisolone, 
etanercept, methotrexate, abatacept, infliximab, tocilizumab, or rituximab. װFor 
descriptive purposes only, so not included in further analysis. ¶higher scores indicate 
more disease activity/pain/disability.
Abbreviations: DMArDs, disease-modifying antirheumatic drugs; Anti-ccP value, 
anti-cyclic citrullinated peptide antibody; rADAi, rheumatoid Arthritis Disease 
Activity index; VAs, Visual Analog scale; hAQ-Di, health Assessment Questionnaire 
Disability index.
Table 2 Psychological factors
Variables Number of  
patients  
providing data
Descriptives
Beliefs about medication
necessity beliefs (5–25)# 536 19.9 (3.5)
concerns beliefs (5–25)# 535 14.3 (3.6)
necessity–concerns  
differential (-20 till +20)‡
527 5.6 (4.7)
Overuse beliefs (4–20)# 546 10.3 (2.5)
harm beliefs (4–20)# 542 10.2 (2.5)
Attitudinal profiles:  
skeptical
527 14 (2.7%)
indifferent 527 25 (4.7%)
Ambivalent 527 244 (46.3%)
Accepting 527 244 (46.3%)
icQ illness cognitions (6–24)#
helplessness 542 11.7 (4.2)
Acceptance 544 17.8 (3.8)
Perceived benefits 538 14.2 (4.5)
UVR self-efficacy (1–5)#
Pain 570 3.6 (0.8)
Physical functioning 566 3.8 (1.1)
symptoms 559 3.9 (0.8)
HADS anxiety/depression  
(0–42)#
567 9.3 (6.5)
Notes: Data are means (standard deviation) or numbers (%). #higher scores 
indicate stronger beliefs, more helplessness/acceptance/perceived benefits, stronger 
self-efficacy concerning pain/physical functioning/symptoms, and more anxiety and 
depression. ‡Differential = necessity score minus concerns score. Positive score 
means that necessity beliefs about medication are stronger than concern beliefs 
about medication.
Abbreviations: ICQ, Illness Cognition Questionnaire; UVR, Arthritis Self-Efficacy 
scale; hADs, hospital Anxiety and Depression scale.
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measure and taking (among others) psychological factors 
into account. Weaker necessity beliefs, a more unfavorable 
balance between necessity and concern beliefs, and having 
an indifferent attitude toward medication were associated 
with CQR non-adherence. Psychological, demographical, 
and clinical factors hardly influenced associations found, and 
thus, some constructs of the BMQ appear to be independent 
predictors of medication non-adherence in RA patients.
Having weaker necessity beliefs about medication was 
the only BMQ construct that was independently associated 
with both CQR and MARS non-adherence. The strength of 
the associations was considerable, as a two unit increase on 
the BMQ necessity scale, for instance, would already yield an 
OR of 0.6 (ie, OR =0.82)41 for patients in being non-adherent 
to medication. This implies that necessity beliefs about 
medication are a sensible target for adherence-improving 
interventions.
According to our results, necessity beliefs about medica-
tion, and not concern beliefs about medication, were asso-
ciated with medication non-adherence. This corresponds 
with three16–18 of the four15–18 previous studies assessing 
associations between beliefs about medication and non-
adherence in RA patients. An explanation for necessity 
beliefs about medication being more important in explaining 
non-adherence than concern beliefs about medication might 
be that feeling the need to take medication is a prerequisite 
for actually taking medicines. So, regardless of the level of 
concerns about medication, patients probably will not take 
their medication if they do not perceive taking medication 
as being necessary.
Table 3 Associations between beliefs about medication and cQr non-adherence
BMQ constructs CQR non-adherence, OR (95% CI)
Unadjusted: Step 1
(n=524–543)
Adjusted: Step 2*
(n=332–344)
Adjusted: Step 3#
(n=297–307)
necessity beliefs 0.9 (0.8–0.9)‡ 0.8 (0.8–0.9)‡ 0.8 (0.8–0.9)‡
concerns beliefs 1.0 (0.9–1.0) 1.0 (0.9–1.1) 1.0 (0.9–1.1)
necessity–concerns differential 0.9 (0.9–1.0)‡ 0.9 (0.9–1.0)‡ 0.9 (0.9–1.0)‡
Overuse beliefs 1.1 (1.0–1.1) 1.1 (1.0–1.2)§ 1.1 (1.0–1.2)
harm beliefs 1.0 (0.9–1.1) 1.1 (1.0–1.2) 1.1 (0.9–1.2)
Attitudinal profilesװ
skeptical 2.5 (0.9–7.2) 1.8 (0.5–5.9) 1.8 (0.5–6.0)
indifferent 3.9 (1.7–8.9)‡ 5.0 (1.3–19.3)§ 5.3 (1.1–25.8)§
Ambivalent 0.8 (0.5–1.2) 0.8 (0.5–1.4) 0.7 (0.4–1.4)
Accepting 0.8 (0.6–1.2) 0.9 (0.5–1.5) 0.9 (0.5–1.7)
Notes: *In Step 2, models were adjusted for age, sex, living with others (yes/no), high education (yes/no), currently employed or studying (yes/no), disease duration, 
n DMArDs used, route of DMArD administration, disease activity (rADAi), and pain (VAs). #in step 3, models were adjusted for the same factors as in step 2, and 
additionally for illness cognitions (ICQ), self-efficacy (UVR), and anxiety/depression (HADS). The HAQ was left out as potential confounder due to multicollinearity with the 
UVr physical functioning scale. ‡P0.01, §P0.05. װreference group = “rest of the patients.” so, for example, the odds for being non-adherent to medication is bigger for 
patients with a skeptical attitude toward medication compared with patients with a non-skeptical attitude toward medication.
Abbreviations: CQR, Compliance Questionnaire Rheumatology; BMQ, Beliefs about Medicines Questionnaire; OR, odds ratio; CI, confidence interval; DMARD, disease-
modifying antirheumatic drug; rADAi, rheumatoid Arthritis Disease Activity index; VAs, Visual Analog scale; icQ, illness cognition Questionnaire; UVr, Arthritis self-
Efficacy Scale; HADS, Hospital Anxiety and Depression Scale; HAQ, Health Assessment Questionnaire; n DMARDs, number of disease-modifying antirheumatic drugs.
80
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40
30
20
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0
80
70
60
50
40
30
20
10
0
5–11 (n=10)
Necessity beliefs: score range (n)
% %
Necessity–concerns differential: score range (n)
12–18 (n=147) 19–25 (n=375) –14 to –3 (n=18) –2 to 9 (n=406) 10–20 (n=100)
Figure 2 Percentage of non-adherent patients per BMQ score range.
Abbreviation: BMQ, Beliefs about Medicines Questionnaire.
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In contrast to most other studies, we were able to examine 
the role of the general medication beliefs in predicting non-
adherence next to the role of necessity and concern beliefs 
about medication. Overall, our results indicate that there 
were no associations between these general harm and general 
overuse beliefs about medication and non-adherence. An 
explanation might be that general beliefs are most relevant 
when new and unfamiliar treatment is prescribed. Their influ-
ence might diminish when patients become more familiar 
with their treatment and as a consequence, start to develop 
necessity and concerns beliefs about their medication.16
We were the first to assess associations between the 
attitudinal profiles and non-adherence in patients with RA. 
Corresponding to other studies,20–22 more non-adherence 
was present in patients with an indifferent attitude toward 
medication compared to patients with an ambivalent or 
accepting attitude toward medication. Maybe, patients with 
an indifferent attitude toward their medication might feel 
less dependent on their medication for controlling their 
disease. This thought is supported by our data; it appears 
that patients with an indifferent attitude toward medica-
tion feel less helpless than patients with a non-indifferent 
attitude toward medication (regression coefficient b: -2.1, 
95% CI: -3.8, -0.4). Also, they have a higher self-efficacy 
related to physical functioning (b: 0.5, 95% CI: 0.1, 1.0). An 
alternate explanation might be that patients with an indif-
ferent attitude toward their medication might also have an 
indifferent attitude toward their health in general.
This study has its strengths and limitations regarding 
internal validity. The first strength is that we assessed asso-
ciations in a large sample of RA patients. Second, we were 
the first to correct for feelings of anxiety/depression, illness 
cognitions, and self-efficacy when modeling associations 
between beliefs about medication and non-adherence, and 
third, we used the validated, dichotomized CQR-score as the 
main adherence measure. However, the CQR is a self-report 
measure of adherence. Self-report measures of adherence 
reflect the patients’ motivation and ability to take medica-
tion, while adherence measured by electronic pill count or 
pharmacy refill data, for example, reflect a different concept: 
availability of medication.18,42 Hence, caution is necessary 
when comparing our results based on self-report with results 
obtained by other adherence measurement methods.18,43 
Also, true ingestion of medication could not be proved by 
self-report. Most other adherence measurement methods also 
suffer from this limitation, however.2 We believe that using 
the CQR for adherence measurement was the best choice for 
this study, because it has been validated against the MEMS 
in RA patients, questionnaires are easy to use, and no gold 
standard to measure adherence is available.2
Due to the cross-sectional design of this study, we were 
not able to assess the causality of associations between beliefs 
about medication and non-adherence. So, it is unclear if 
beliefs about medication led to non-adherence or whether 
non-adherent behavior influenced beliefs.44 However, there 
still is insufficient knowledge about the presence (or absence) 
of longitudinal associations between beliefs about medication 
and non-adherence.45 Like adherence itself, beliefs about 
medication might change over time. A high level of necessity 
beliefs about medication might correlate well with adherent 
behavior at that same time, but might not be predictive of 
adherent behavior in the future. So, cross-sectional designs 
might be as informative as longitudinal designs.
This study also has its strengths and limitations regarding 
external validity. On average, our sample of RA patients had 
a long disease duration (median: 14 years), making our 
results not generalizable to patients with recently diagnosed 
RA. However, our population did not differ from other RA 
populations15–17 on other demographic and clinical charac-
teristics, making our results generalizable to RA populations 
with a long disease duration.
Practice implications
Attempts to increase necessity beliefs about medication in RA 
patients might be worthwhile in improving medication adher-
ence. However, strong evidence about effective interventions 
to increase necessity beliefs about medication is currently 
absent. Development of such interventions and research into 
the effectiveness of these interventions is needed.
Although the strength of the association between having 
an indifferent attitude towards medication and medication 
non-adherence was considerable, targeting patients with 
such an indifferent attitude is not sensible in clinical practice 
because of the low prevalence (4%; 580 patients need to be 
screened to detect 25 indifferent patients).
Conclusion
Weaker necessity beliefs about medication, a more unfa-
vorable balance between necessity and concern beliefs 
about medication, and having an indifferent attitude toward 
medication are associated with medication non-adherence. 
Psychological factors hardly confound those associations. 
Of the BMQ constructs associated with non-adherence, 
increasing necessity beliefs about medication in clinical 
practice might be most worthwhile to improve medication 
adherence in RA patients.
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Supplementary materials
To obtain a dichotomous Compliance Questionnaire Rheu-
matology (CQR) non-adherence score, first a discriminant Z 
score (which has been validated against a Medication Event 
Monitoring System [MEMS] taking compliance of 80%) 
has to be calculated.
The CQR has 19 items, which reflect statements about 
drug-taking behavior. Patients respond to a 4-point Likert 
scale ranging from 1, “don’t agree at all,” to 4, “agree very 
much”; items 4, 8, 9, 11, 12, and 19 have to be reversely 
recoded (4=1, 3=2, etc). Missing items are substituted with 
the patient’s average on all non-missing items when the 
amount of missing items is smaller than four; otherwise, no 
Table S1 Details of used questionnaires (except beliefs and adherence)
Secondary outcome 
measure
Questionnaire Description
rheumatoid arthritis  
(rA) disease activity
rheumatoid  
Arthritis Disease  
Activity index  
(rADAi)2
Five items, measuring global disease activity/pain, current duration of morning stiffness, 
and current tender joints. score range: 0–10, with higher scores indicating more 
disease activity
Patient’s usual  
abilities in past week
health Assessment  
Questionnaire  
Disability index  
(hAQ-Di)3
Twenty items, measuring eight dimensions of functioning (dressing and grooming, arising, 
eating, walking, hygiene, reaching, gripping, and common daily activities). greater than 
or equal to six dimensions need a valid score to obtain the total score. score range: 
0–3, with higher scores indicating more disability. note that we took aids and devices 
into account in calculating the hAQ-Di score
Pain severity hAQ Visual Analog  
scale (VAs)3,4
scale range: 0 mm (no pain) to 100 mm (unbearable pain)
illness cognitions illness cognition  
Questionnaire  
(icQ)5
Three subscales of six items each, measuring “helplessness” as a way of emphasizing 
the aversive meaning of a disease, “acceptance” as a way to diminish this aversive meaning, 
and “perceived benefits” as a way of adding a positive meaning to a disease. Score range: 
6–24, with higher scores indicating more helplessness, acceptance, and perceived benefits
Self-efficacy Arthritis Self-Efficacy  
scale (UVr)6,7
Measures the patient’s perceived ability to perform specific behaviors aimed at controlling 
disability. The UVR has three subscales: self-efficacy related to physical function (eight items), 
to coping with pain (five items), and to coping with other symptoms associated with arthritis 
(such as depression and fatigue, six items)
Score range: 1–5, with higher scores indicating stronger self-efficacy
Anxiety and  
depression
hospital Anxiety and  
Depression scale  
(hADs)8
14 items, total score range: 0–42, with higher scores indicating a higher degree of anxiety/
depression
The hADs has two subscales, one for anxiety and one for depression, with seven items per 
scale. subscale score range: 0–21; subscale scores higher than 8 are indicative of anxiety 
or depression
Note: All items in a questionnaire need a valid answer to obtain a total score, unless mentioned otherwise.
score is calculated. The Z score is calculated by means of 
the following function:
Z score = -3.4777 - (0.4448*cqr1) - (0.9517*cqr2) 
+ (1.6758*cqr3) - (0.2101*cqr4) + 
(0.0244*cqr5) -(0.5353*cqr6) + (0.003*cqr7) + 
(0.0135*cqr8) - (0.0106*cqr9) -(0.2546*cqr10) 
+(0.1023*cqr11) + (0.1155*cqr12) 
+(0.0248*cqr13) + (0.1091*cqr14) 
+ (0.4475*cqr15) + (0.2284*cqr16) 
+ (0.535*cqr17) - (0.4191*cqr18) + 
(0.6829*cqr19). (1)
Non-adherence is defined when subjects have a Z score 
-0.5849. For more information about the CQR, see de 
Klerk et al.1
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Table S2 The contribution of single, psychological factors to associations between beliefs about medication and cQr non-adherence 
(corrected for demographic and clinical factors)
CQR non-adherence, OR (95% CI)
Necessity  
beliefs
Concern  
beliefs
NC  
differential
Overuse  
beliefs
Harm  
beliefs
Attitudinal profiles
Skeptical Indifferent Ambivalent Accepting
Basic, adjusted model  
(including demographic  
and clinical variables)*
0.8  
(0.8–0.9)#
1.0  
(0.9–1.1)
0.9  
(0.9–1.0)#
1.1  
(1.0–1.2)‡
1.1  
(1.0–1.2)
1.8  
(0.5–5.9)
5.0  
(1.3–19.3)‡
0.8  
(0.5–1.4)
0.9 
(0.5–1.5)
+ icQ helplessness§ – – – – – – – 0.9  
(0.5–1.6)
0.8 
(0.5–1.3)
+ icQ acceptance|| – – – – – – – 0.6  
(0.4–1.1)
1.1 
(0.6–1.9)
+ icQ perceived  
benefits
– – – – – – 6.9  
(1.5–32.2)‡
0.7  
(0.4–1.2)
1.0 
(0.6–1.6)
+ UVR self-efficacy pain – – – – – – – – –
+ UVR self-efficacy  
physical functioning
– – – – – – – – –
+ UVR self-efficacy  
symptoms
– – – – – – – – –
+ HADS anxiety/ 
depression
– – – – – – – – –
Notes: *Each of these models is adjusted for age, sex, living with others (yes/no), high education (yes/no), currently employed or studying (yes/no), disease duration, n 
DMArDs used, route of DMArD administration, disease activity (rADAi) and pain (VAs). #P0.01. ‡P0.05. §Basic, adjusted model (corrected for demographic and clinical 
variables) and icQ helplessness. ||Basic, adjusted model (corrected for demographic and clinical variables) and icQ acceptance (etc). Data are shown as cQr non-adherence, 
Or (95% ci).
Abbreviations: CQR, Compliance Questionnaire Rheumatology; OR, odds ratio; NC, necessity concerns; ICQ, Illness Cognition Questionnaire; UVR, Arthritis Self-Efficacy 
scale; hADs, hospital Anxiety and Depression scale; rADAi, rheumatoid Arthritis Disease Activity index; VAs, Visual Analog scale; n DMArDs, number of disease-
modifying antirheumatic drugs.
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